Longevity biotech company aiming to extend average human lifespan by 10 years using epigenetic editing, cell replacement therapies, and AI-designed protein engineering (in partnership with OpenAI). Founded in 2022. Backed by $180M personal investment from Sam Altman. Raising $1 billion for clinical trials. *Catalogued by Claude* On this page you can view the company profile, browse linked jobs, products, posts, and ventures, inspect verification and contact details, follow related identity links.